- Home
- RILY vs ADCT Comparison
RILY vs ADCT Comparison
Compare RILY & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RILY
- ADCT
- Stock Information
- Founded
- RILY 1973
- ADCT 2011
- Country
- RILY United States
- ADCT Switzerland
- Employees
- RILY N/A
- ADCT N/A
- Industry
- RILY Investment Managers
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- RILY Finance
- ADCT Health Care
- Exchange
- RILY Nasdaq
- ADCT Nasdaq
- Market Cap
- RILY 142.1M
- ADCT 143.1M
- IPO Year
- RILY 2007
- ADCT 2020
- Fundamental
- Price
- RILY $4.37
- ADCT $1.72
- Analyst Decision
- RILY
- ADCT Strong Buy
- Analyst Count
- RILY 0
- ADCT 5
- Target Price
- RILY N/A
- ADCT $8.50
- AVG Volume (30 Days)
- RILY 4.5M
- ADCT 374.9K
- Earning Date
- RILY 03-17-2025
- ADCT 05-05-2025
- Dividend Yield
- RILY 11.55%
- ADCT N/A
- EPS Growth
- RILY N/A
- ADCT N/A
- EPS
- RILY N/A
- ADCT N/A
- Revenue
- RILY $854,383,000.00
- ADCT $70,717,000.00
- Revenue This Year
- RILY N/A
- ADCT $6.81
- Revenue Next Year
- RILY N/A
- ADCT $11.24
- P/E Ratio
- RILY N/A
- ADCT N/A
- Revenue Growth
- RILY N/A
- ADCT N/A
- 52 Week Low
- RILY $2.73
- ADCT $1.39
- 52 Week High
- RILY $40.09
- ADCT $5.38
- Technical
- Relative Strength Index (RSI)
- RILY 45.82
- ADCT 51.03
- Support Level
- RILY $4.70
- ADCT $1.50
- Resistance Level
- RILY $5.82
- ADCT $1.89
- Average True Range (ATR)
- RILY 1.07
- ADCT 0.14
- MACD
- RILY -0.04
- ADCT 0.02
- Stochastic Oscillator
- RILY 36.61
- ADCT 57.14
About RILY B. Riley Financial Inc.
B. Riley Financial Inc is a diversified financial services company. The company through its subsidiaries offers investment banking and financial services to corporate, institutional, and high-net-worth clients and also asset disposition, valuation and appraisal, and capital advisory services to retail, wholesale, institutional, lenders, capital providers, private equity investors, and professional services firms in United States, Canada, and Europe. It also provides internet access and subscription services. The reportable operating segments of the company include Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications segment, and Consumer products segment.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.